Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PRS129
MIFTS: 48

Prostatic Hyperplasia, Benign

Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Prostatic Hyperplasia, Benign

About this section

MalaCards integrated aliases for Prostatic Hyperplasia, Benign:

Name: Prostatic Hyperplasia, Benign 57
Benign Prostatic Hyperplasia 55 73
Prostatic Hyperplasia 73
Bph 57

Characteristics:

OMIM:

57
Inheritance:
autosomal dominant


HPO:

32
prostatic hyperplasia, benign:
Inheritance autosomal dominant inheritance
Onset and clinical course infantile onset


External Ids:

OMIM 57 600082
MedGen 42 C1704272
SNOMED-CT via HPO 69 263681008 266569009
Sources

Summaries for Prostatic Hyperplasia, Benign

About this section
OMIM : 57 Benign prostatic hyperplasia (BPH) refers to the nonmalignant growth of the prostate gland, and is histologically defined as hyperplasia of the prostate gland. BPH is an age-related phenomenon in men beginning at about age 40 years. BPH may result in prostatic enlargement and clinical symptoms most commonly affecting the lower urinary tract. These symptoms may be obstructive, including hesitancy, weak flow, and urinary retention, or irritative, including increased frequency and urgency. However, not all men with histologic BPH will develop prostatic enlargement or urinary symptoms (review by Roehrborn, 2005). (600082)

MalaCards based summary : Prostatic Hyperplasia, Benign, also known as benign prostatic hyperplasia, is related to prostatic adenoma and prostatic hypertrophy, and has symptoms including prostatism An important gene associated with Prostatic Hyperplasia, Benign is KLK3 (Kallikrein Related Peptidase 3), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Bupivacaine and Doxazosin have been mentioned in the context of this disorder. Affiliated tissues include prostate, testes and kidney, and related phenotype is benign prostatic hyperplasia.

Wikipedia : 76 Benign prostatic hyperplasia (BPH), also called prostate enlargement, is a noncancerous increase in size... more...

Sources

Related Diseases for Prostatic Hyperplasia, Benign

About this section

Diseases related to Prostatic Hyperplasia, Benign via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 29)
# Related Disease Score Top Affiliating Genes
1 prostatic adenoma 33.2 AR KLK3
2 prostatic hypertrophy 31.2 ADRA1A AR CYP19A1 KLK3
3 prostatitis 29.8 ADRA1A KLK3
4 prostate cancer 27.8 AR CYP19A1 FGF2 FOLH1 GSTP1 KLK3
5 prostate disease 11.3
6 prostatic acinar adenocarcinoma 10.6 AR KLK3
7 penis agenesis 10.6 AR SRD5A2
8 withdrawal disorder 10.5 AR KLK3
9 breast cyst 10.5 KLK3 SERPINA3
10 villous adenoma 10.5 FOLH1 KLK3
11 sexual disorder 10.5 KLK3 PDE5A
12 cystitis cystica 10.4 AR KLK3
13 androgen insensitivity, partial 10.4 AR CYP19A1
14 transsexualism 10.3 AR CYP19A1
15 gender identity disorder 10.3 AR CYP19A1
16 nodular prostate 10.3 AR FOLH1 KLK3
17 complete androgen insensitivity syndrome 10.2 AR CYP19A1
18 sex differentiation disease 10.2 AR CYP19A1
19 androgen insensitivity syndrome 10.1 AR SRD5A2
20 androgenic alopecia 10.1 AR CYP19A1 KLK3
21 gynecomastia 10.1 AR CYP19A1 KLK3
22 reproductive system disease 10.1 AR CYP19A1 KLK3
23 alopecia, androgenetic, 1 10.0 AR CYP19A1 SRD5A2
24 pseudohermaphroditism 10.0 AR CYP19A1 SRD5A2
25 impotence 9.8
26 proctitis 9.7 FGF2 KLK3
27 suppression of tumorigenicity 12 9.7 AR FOLH1 GSTP1 KLK3
28 juvenile nasopharyngeal angiofibroma 9.3 CYP19A1 FGF2
29 male reproductive organ cancer 9.2 AR FOLH1 GSTP1 KLK3 PSCA

Graphical network of the top 20 diseases related to Prostatic Hyperplasia, Benign:



Diseases related to Prostatic Hyperplasia, Benign
Sources

Symptoms & Phenotypes for Prostatic Hyperplasia, Benign

About this section

Symptoms via clinical synopsis from OMIM:

57
GU:
benign prostatic hyperplasia

Misc:
early age of onset


Clinical features from OMIM:

600082

Human phenotypes related to Prostatic Hyperplasia, Benign:

32
# Description HPO Frequency HPO Source Accession
1 benign prostatic hyperplasia 32 HP:0008711

UMLS symptoms related to Prostatic Hyperplasia, Benign:


prostatism
Sources

Drugs & Therapeutics for Prostatic Hyperplasia, Benign

About this section

Drugs for Prostatic Hyperplasia, Benign (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 216)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bupivacaine Approved, Investigational Phase 4,Not Applicable 2180-92-9, 38396-39-3 2474
2
Doxazosin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 74191-85-8 3157
3
Alfuzosin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 81403-80-7 2092
4
Finasteride Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 98319-26-7 57363
5
Tamsulosin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106133-20-4 129211
6
Dutasteride Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 164656-23-9 152945 6918296
7
Ethanol Approved Phase 4,Phase 1,Phase 2,Not Applicable 64-17-5 702
8
Tadalafil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 171596-29-5 110635
9
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Not Applicable 437-38-7 3345
10
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
11
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
12
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
13
Dihydrotachysterol Approved Phase 4,Phase 1,Phase 2 67-96-9 5281010 5311071
14
Celecoxib Approved, Investigational Phase 4,Phase 2 169590-42-5 2662
15
Acetylcholine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-84-3 187
16
Tranexamic Acid Approved Phase 4 1197-18-8 5526
17
Prazosin Approved Phase 4,Phase 2,Not Applicable 19216-56-9 4893
18
Terazosin Approved Phase 4,Phase 2,Not Applicable 63590-64-7 5401
19
Testosterone undecanoate Approved, Investigational Phase 4,Phase 2 5949-44-0
20
Testosterone Approved, Investigational Phase 4,Phase 2 58-22-0 6013
21
Silodosin Approved Phase 4,Phase 3,Phase 2 160970-54-7
22
Fesoterodine Approved Phase 4 286930-03-8, 286930-02-7 6918558
23
Methyltestosterone Approved Phase 4,Phase 2 58-18-4 6010
24 Mirabegron Approved Phase 4,Phase 2 223673-61-8 9865528
25
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
26
Testosterone enanthate Approved Phase 4,Phase 2 315-37-7 9416
27
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 26757 5195
28
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 1 77-92-9 311
29 Naftopidil Investigational Phase 4,Phase 3 57149-07-2
30
Dihydrotestosterone Illicit, Investigational Phase 4,Phase 1,Phase 2,Early Phase 1 521-18-6 10635
31
Fibrinolysin Investigational Phase 4 9004-09-5
32 Permixon Phase 4,Phase 3,Phase 2,Not Applicable
33 Solifenacin succinate Phase 4,Phase 3,Phase 2,Phase 1 242478-38-2
34 Tolterodine tartrate Phase 4 124937-52-6
35 calcium channel blockers Phase 4,Phase 3
36 5-alpha Reductase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Central Nervous System Depressants Phase 4,Phase 1,Phase 2,Not Applicable
38 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Adrenergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Mitogens Phase 4,Not Applicable
43 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
44 Muscarinic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
45 Cholinergic Antagonists Phase 4,Phase 3,Phase 2,Phase 1
46 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Androgens Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
49 Anesthetics Phase 4,Phase 1,Phase 2,Not Applicable
50 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 485)
# Name Status NCT ID Phase Drugs
1 A Study Comparing Photoselective Vaporization of the Prostate With the GreenLight XPSâ„¢ Laser System and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Hyperplasia Unknown status NCT01218672 Phase 4
2 Comparison Between Alpha Blocker Monotherapy and 5ARI Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia (BPH) Unknown status NCT01301599 Phase 4 combination therapy;alpha blocker monotherapy;5 alpha reductase inhibitor monotherapy
3 Clinical Study to Assess the Influence of a Saw Palmetto Preparation in Patients With Benign Prostatic Hyperplasia (BPH) and Sexual Dysfunctions Unknown status NCT01021267 Phase 4 Saw palmetto berry extract
4 Prostatic Artery Embolization Versus 532 nm Green Light PVP for Catheterized Patients Unknown status NCT02006303 Phase 4
5 A Study to Determine the Improvement of the Symptoms of Benign Prostatic Hyperplasia (BPH) When Switching Subjects From Proscar to Avodart Unknown status NCT00690950 Phase 4 Dutasteride
6 Combination Treatment With Doxazosin Plus TolterodineSR 2 mg Versus 4mg in Men With an Overactive Bladder (OAB) and Benign Prostatic Hyperplasia (BPH) Unknown status NCT00922506 Phase 4 doxazosin plus tolterodine SR
7 Advanced Benefits of Alpha-blocker Monotherapy on Lower Urinary Tracts Symptoms(LUTS) Patients Unknown status NCT01736033 Phase 4 Tamsulosin;Finasteride;Placebo
8 Trial of HoLEP vs. PVP in Treating BPH in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
9 Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia Unknown status NCT02034604 Phase 4 Naftofidil;Tamsulosin
10 Kinetics of the Finasteride Prostate Induced Apoptosis Unknown status NCT00130767 Phase 4 finasteride
11 Ejaculatory Sparing vs. Non-ejaculatory Sparing GreenLight Laser Photoselective Vaporization of the Prostate Unknown status NCT02749604 Phase 4
12 Low Dose Bupivacaine Spinal for Trans Uretral Prostatectomy. Unknown status NCT01861041 Phase 4 Heavy Bupivacaine;Isobaric Bupivacaine
13 Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications Unknown status NCT01876836 Phase 4
14 Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP) Unknown status NCT00826527 Phase 4 Solifenacin PO
15 Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH) Completed NCT01259531 Phase 4 Silodosin
16 FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244255 Phase 4 FLOMAX® capsules;Ascending doses of HYTRIN® capsules
17 Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia Completed NCT02106182 Phase 4 Silodosin
18 A Long-Term Study Examining the Treatment of Benign Prostatic Hyperplasia With Photoselective Vaporization Completed NCT00465101 Phase 4
19 Study to Evaluate the Symptomatic Relief Effects of FLOMAX® in Patients With Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244242 Phase 4 Tamsulosin hydrochloride
20 Effectiveness and Safety of Silodosin in the Treatment of Benign Prostatic Hyperplasia Completed NCT01757769 Phase 4 Silodosin
21 Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia Completed NCT01500057 Phase 4
22 Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin Completed NCT00401661 Phase 4 Alfuzosin
23 Comparative Efficacy of Dutasteride Plus Tamulosin With Lifestyle Advice Versus Watchful Waiting Plus Lifestyle Advice in the Management of Treatment naïve Men With Moderately Symptomatic Benign Prostatic Hyperplasia and Prostate Enlargement Completed NCT01294592 Phase 4 Dutasteride plus tamsulosin;tamsulosin
24 Dutasteride and Flex Dose of Tamsulosin on as Needed Basis, to Treat Benign Prostatic Hyperplasia Completed NCT00701779 Phase 4 Tamsulosin
25 Clinical Trial to Evaluate the Efficacy and Safety of Naftopidil in Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia Completed NCT01922375 Phase 4 Naftopidil
26 Study to Evaluate the Therapeutic Action of Tamsulosin and Finasteride in Symptomatic Benign Prostatic Hyperplasia (BPH) Patients Completed NCT02244229 Phase 4 Tamsulosin;Finasteride;Placebo
27 Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer Completed NCT00375765 Phase 4 Dutasteride
28 Study to Characterise the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms Completed NCT02245490 Phase 4 Tamsulosin HCl controlled release capsules;Matching placebo capsule
29 SAMBA: Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin Completed NCT00486785 Phase 4 Alfuzosin
30 Solifenacin as Add-on Therapy for Overactive Bladder Symptoms in Men Treated for Benign Prostatic Hyperplasia Completed NCT00771394 Phase 4 Tamsulosin hydrochloride;Solifenacin succinate
31 Benign Prostatic Hyperplasia (BPH) Screening Tool Case Finding Study in Subjects >=50 Years Completed NCT02757963 Phase 4
32 TRADE-Testosterone Replacement and Dutasteride Effectiveness Completed NCT00194675 Phase 4 Dutasteride;Testosterone gel;Placebo dutasteride
33 A Study of Tadalafil (LY450190) in Participants With Lower Urinary Tract Symptoms (LUTS) Suggestive of Benign Prostatic Hyperplasia LUTS (BPH-LUTS). Completed NCT02431754 Phase 4 Tadalafil;Placebo;Alpha1 Blocker
34 ALF-ONE : ALFuzosin ONcE Daily Completed NCT00280605 Phase 4 Alfuzosin
35 KTP Green Light Prostatectomy Compared With Open Prostatectomy Completed NCT02072499 Phase 4
36 PERmixon® in LUTS Evaluation Study (PERLES) Completed NCT02121613 Phase 4 Permixon® 160 mg;Tamsulosine LP;Placebo matching Permixon® 160 mg;Placebo matching Tamsulosine LP
37 Once Daily Given Alfuzosin in the Treatment of BPH Completed NCT00637715 Phase 4 Alfuzosin
38 Exploratory Study of L.S.E.S.r. (LipidoSterolic Extract of Serenoa Repens)(PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in Urinary Symptoms Related to BPH (Benign Prostatic Hyperplasia) Completed NCT01604811 Phase 4 Permixon® 160 mg;Tamsulosine Arrow LP;Placebo matching Permixon® 160 mg;Placebo matching Tamsulosine Arrow LP
39 A Phase 4 Study With Tamsulosin OCAS to Assess Nighttime Voiding. Completed NCT00379067 Phase 4 Tamsulosin OCAS;Placebo
40 The Effects of α-adrenergic Receptor Antagonists on Choroid and Pupil Completed NCT03144596 Phase 4 Alfuzosin Hydrochloride 10 MG;Tamsulosin Hydrochloride 0.4 MG
41 Male Sexual Health Questionnaire (MSHQ) - Sexual Function Study Completed NCT00427882 Phase 4 ALFUZOSIN
42 A Prospective Evaluation of the GreenLight Model 120 Laser Completed NCT00364585 Phase 4
43 A Study to Evaluate the Tolerability and Efficacy of Tamsulosin 0.4mg OCAS Formulation in Patients Who Are Unsatisfied With the Treatment of Tamsulosin 0.2mg Conventional Formulation Completed NCT02180789 Phase 4 Tamsulosin OCAS
44 Evaluation Of The Efficacy And Safety Of The Doxasozin Gastrointestinal Therapeutic System (GITS) In Patients With Prostate Enlargement Completed NCT00648323 Phase 4 Doxazosin mysylate GITS
45 Effectiveness and Safety of Viagra in Men With ED and LUTS Due to Benign Prostatic Hyperplasia (BPH) Completed NCT00143221 Phase 4 Viagra;Placebo
46 Effect of Dutasteride on HIF-1alpha and VEGF in the Prostate Completed NCT00880672 Phase 4 dutasteride
47 Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration Completed NCT02041767 Phase 4 Ertapenem
48 Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic Obstruction Completed NCT00827814 Phase 4 Dutasteride
49 Holmium Laser Enucleation of Prostate(HOLEP) vs Greenlight(XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP) Completed NCT01494337 Phase 4
50 TRT on BPH Hypoganadal MetS Patients. Florence-PROTEST Completed NCT02366975 Phase 4 Testosterone gel 2%

Search NIH Clinical Center for Prostatic Hyperplasia, Benign

Inferred drug relations via UMLS 73 / NDF-RT 51 :
Sources

Genetic Tests for Prostatic Hyperplasia, Benign

About this section
Sources

Anatomical Context for Prostatic Hyperplasia, Benign

About this section

MalaCards organs/tissues related to Prostatic Hyperplasia, Benign:

41
Prostate, Testes, Kidney, Endothelial, Heart, Liver, Bone
Sources

Publications for Prostatic Hyperplasia, Benign

About this section

Articles related to Prostatic Hyperplasia, Benign:

(show top 50) (show all 1109)
# Title Authors Year
1
Comparison of the Effect of Naftopidil 75 mg and Tamsulosin 0.2 mg on the Bladder Storage Symptom With Benign Prostatic Hyperplasia: Prospective, Multi-institutional Study. ( 28624553 )
2018
2
Effects of<i>Panax ginseng</i>on the nerve growth factor expression in testosterone induced benign prostatic hyperplasia. ( 29379359 )
2018
3
Three-Year Outcomes of the Prospective, Randomized Controlled RezA<m System Study: Convective Radiofrequency Thermal Therapy for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. ( 29122620 )
2018
4
WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia. ( 29360529 )
2018
5
A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). ( 29044968 )
2018
6
Association of ANRIL gene polymorphisms with prostate cancer and benign prostatic hyperplasia in an Iranian population. ( 28621612 )
2017
7
Effects of a co-micronized composite containing palmitoylethanolamide and polydatin in an experimental model of benign prostatic hyperplasia. ( 28610993 )
2017
8
Correlation of Subjective Symptoms in Patients with Benign Prostatic Hyperplasia and Erectile Dysfunction. ( 28428671 )
2017
9
Management of Benign Prostatic Hyperplasia: Could Dietary Polyphenols Be an Alternative to Existing Therapies? ( 28503148 )
2017
10
A genetic variant near GATA3 implicated in inherited susceptibility and etiology of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). ( 28656603 )
2017
11
Prostate Artery Embolization for Benign Prostatic Hyperplasia: Current Status. ( 27887933 )
2017
12
The influence of asymptomatic inflammatory prostatitis on the onset and progression of lower urinary tract symptoms in men with histologic benign prostatic hyperplasia. ( 29264225 )
2017
13
Molecular Analysis of the SRD5A1 and SRD5A2 Genes in Patients with Benign Prostatic Hyperplasia with Regard to Metabolic Parameters and Selected Hormone Levels. ( 29084161 )
2017
14
Oxidative stress parameters in patients with prostate cancer, benign prostatic hyperplasia and asymptomatic inflammatory prostatitis: A prospective controlled study. ( 29211357 )
2017
15
Association of increased urine brain derived neurotrophic factor with lower urinary tract symptoms in men with benign prostatic hyperplasia. ( 28786061 )
2017
16
Cancer/testis antigen SPATA19 is frequently expressed in benign prostatic hyperplasia and prostate cancer. ( 28972294 )
2017
17
Administration of daily 5a88mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia. ( 28830281 )
2017
18
Adiponectin deficiency contributes to the development and progression of benign prostatic hyperplasia in obesity. ( 28256562 )
2017
19
Targeting phenotypic heterogeneity in benign prostatic hyperplasia. ( 28800482 )
2017
20
Mitochondrion-associated protein peroxiredoxin 3 promotes benign prostatic hyperplasia through autophagy suppression and pyroptosis activation. ( 29113303 )
2017
21
Functional outcomes and complications following B-TURP versus HoLEP for the treatment of benign prostatic hyperplasia: a review of the literature and Meta-analysis. ( 28368238 )
2017
22
HOTAIR genetic variants are associated with prostate cancer and benign prostate hyperplasia in an Iranian population. ( 28259691 )
2017
23
The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases with Benign Prostatic Hyperplasia. ( 28937828 )
2017
24
Efficacy and safety of tadalafil 5 mg once daily in the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia in men aged a8Y75 years: integrated analyses of pooled data from multinational, randomized, placebo-controlled clinical studies. ( 27988986 )
2017
25
Early Experiences of Contact Laser Vaporization of the Prostate using the 980a88nm High Power Diode Laser for Benign Prostatic Hyperplasia. ( 28573791 )
2017
26
Aquablation of the Prostate for Symptomatic Benign Prostatic Hyperplasia: 1-Year Results. ( 28111300 )
2017
27
Relationship of oestrogen receptor alpha gene polymorphisms with risk for benign prostatic hyperplasia and prostate cancer in Chinese men. ( 28353585 )
2017
28
Genetic association between PSA-158G/A polymorphism and the susceptibility of benign prostatic hyperplasia: a meta-analysis. ( 28430620 )
2017
29
The American Urological Association Symptom Index for Benign Prostatic Hyperplasia. ( 28012747 )
2017
30
Seasonal Changes in Lower Urinary Tract Symptoms in Japanese Men With Benign Prostatic Hyperplasia Treated With I+<sub>1</sub>-Blockers. ( 28954461 )
2017
31
Elevated insulin and reduced insulin like growth factor binding protein-3/prostate specific antigen ratio with increase in prostate size in Benign Prostatic Hyperplasia. ( 28300542 )
2017
32
Clinical evaluation of embolization of the superior vesical prostatic artery for treatment of benign prostatic hyperplasia: a single-center retrospective study. ( 29362657 )
2017
33
Metastatic Malignant Melanoma of the Urinary Bladder in a Patient With Benign Prostatic Hyperplasia and Urethral Stricture. ( 27491496 )
2016
34
A Randomized, Open-Label, Comparative Study of Efficacy and Safety of Tolterodine Combined with Tamsulosin or Doxazosin in Patients with Benign Prostatic Hyperplasia. ( 27260129 )
2016
35
Monopolar versus bipolar transurethral resection of prostate for benign prostatic hyperplasia: Operative outcomes and surgeon preferences, a real-world scenario. ( 27453650 )
2016
36
ADME studies and preliminary safety pharmacology of LDT5, a lead compound for the treatment of benign prostatic hyperplasia. ( 27901175 )
2016
37
Benign prostatic hyperplasia, metabolic syndrome and androgenic alopecia: Is there a possible relationship? ( 27489744 )
2016
38
Cyclooxygenase 2 (rs2745557) Polymorphism and the Susceptibility to Benign Prostate Hyperplasia and Prostate Cancer in Egyptians. ( 26920155 )
2016
39
Vitamin D Deficiency as a Potential Marker of Benign Prostatic Hyperplasia. ( 27327576 )
2016
40
Risk of erectile dysfunction associated with use of 5-I+ reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink. ( 27659058 )
2016
41
Detection of Trichomonas vaginalis in prostate tissue and serostatus in patients with asymptomatic benign prostatic hyperplasia. ( 27660027 )
2016
42
Analysis of Urinary Prostate-Specific Antigen Glycoforms in Samples of Prostate Cancer and Benign Prostate Hyperplasia. ( 27065039 )
2016
43
Life-threatening urethral hemorrhage after placement of a Foley catheter in a patient with uroseptic disseminated intravascular coagulation due to chronic urinary retention induced by untreated benign prostatic hyperplasia. ( 29123824 )
2016
44
Biased I+-adrenergic receptor and I^arrestin signaling in a cell culture model of benign prostatic hyperplasia. ( 26850854 )
2016
45
Smoking habits and benign prostatic hyperplasia: A systematic review and meta-analysis of observational studies. ( 27512883 )
2016
46
Interactions between medications employed in treating benign prostatic hyperplasia and food - A short review. ( 27551761 )
2016
47
Examination of CK2I+ and NF-I_B p65 expression in human benign prostatic hyperplasia and prostate cancer tissues. ( 27435858 )
2016
48
Bacteriological Profile of Isolates From Urine Samples in Patients of Benign Prostatic Hyperplasia and or Prostatitis Showing Lower Urinary Tract Symptoms. ( 27891339 )
2016
49
Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States. ( 27668569 )
2016
50
[Prostatic urethral lift: A novel minimally invasive treatment for benign prostatic hyperplasia]. ( 29019232 )
2016
Sources

Variations for Prostatic Hyperplasia, Benign

About this section
Sources

Expression for Prostatic Hyperplasia, Benign

About this section
Search GEO for disease gene expression data for Prostatic Hyperplasia, Benign.
Sources

Pathways for Prostatic Hyperplasia, Benign

About this section

Pathways related to Prostatic Hyperplasia, Benign according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Endometrial cancer 37
Show member pathways
 12.3 AR GSTP1 KLK3 SRD5A2
2
Pathways in cancer 37
11.74 AR FGF17 FGF2 GSTP1 KLK3
3
Transcription Androgen Receptor nuclear signaling 22
Show member pathways
 11.3 AR KLK3 SRD5A2
4
Sympathetic Nerve Pathway (Neuroeffector Junction) 61
10.52 ADRA1A ADRA1D
Sources

GO Terms for Prostatic Hyperplasia, Benign

About this section

Biological processes related to Prostatic Hyperplasia, Benign according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.83 ADRA1D AR FGF17 FGF2
2 negative regulation of extrinsic apoptotic signaling pathway GO:2001237 9.55 AR GSTP1
3 positive regulation of vasoconstriction GO:0045907 9.54 ADRA1A ADRA1D
4 sex differentiation GO:0007548 9.51 AR SRD5A2
5 positive regulation of cardiac muscle hypertrophy GO:0010613 9.49 ADRA1A PDE5A
6 positive regulation of smooth muscle contraction GO:0045987 9.48 ADRA1A ADRA1D
7 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.46 ADRA1A ADRA1D
8 androgen metabolic process GO:0008209 9.43 CYP19A1 SRD5A2
9 regulation of systemic arterial blood pressure GO:0003073 9.4 AR KLK3
10 adrenergic receptor signaling pathway GO:0071875 9.37 ADRA1A ADRA1D
11 prostate gland growth GO:0060736 9.32 AR CYP19A1
12 female genitalia development GO:0030540 9.26 CYP19A1 SRD5A2
13 testosterone biosynthetic process GO:0061370 9.16 CYP19A1 SRD5A2
14 cell-cell signaling GO:0007267 9.02 ADRA1A ADRA1D AR FGF17 SRD5A2
15 norepinephrine-epinephrine vasoconstriction involved in regulation of systemic arterial blood pressure GO:0001994 8.96 ADRA1A ADRA1D

Molecular functions related to Prostatic Hyperplasia, Benign according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fibroblast growth factor receptor binding GO:0005104 9.16 FGF17 FGF2
2 adrenergic receptor activity GO:0004935 8.96 ADRA1A ADRA1D
3 alpha1-adrenergic receptor activity GO:0004937 8.62 ADRA1A ADRA1D
Sources

Sources for Prostatic Hyperplasia, Benign

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....